

Date: 30-01-2023

To, Cooperate Relation Department The BSE LIMITED 1st Floor, Phiroze leejeebhoy Towers, Dalal Street, Mumbai-400001

Script Code: 531210

Dear Sir/ Madam,

Sub: Newspaper clipping of the Un-Audited Financial Results pursuant to Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015 for the Quarter and Half Year Ended on 31st December 2022.

Please find enclosed herewith Newspaper clippings of Un-Audited Financial Results for the quarter and half year ended on 31st December 2022 published in FREE PRESS JOURNAL and NAVSHAKTI on 29th January,2023 in pursuance of Regulation 47(3) of SEBI (Listing obligations and Disclosure Requirements) Regulations, 2015, which were approved in the Board meeting held on 28th January,2023.

Kindly acknowledge the receipt of the same and update in your records.

Thanking you,

Yours faithfully, For Colinz Laboratories Ltd.,

Dr. Mani L. S.

Director & Company Secretary

DIN: 00825886

#### Colinz Laboratories Limited

## \* NAV SHAKTI

## Date: 29/01/2023

## विवास शक्ति।मुंबई, रविवार, २९ जानेवारी २०२३

## **COLINZ LABORATORIES LIMITED**

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078. (CIN NO : L24200MH1986PLC041128)

## EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER ENDED 31st December, 2022

		( Rs. In "Lacs")						
S. No.	PARTICULARS	QUARTER ENDED Un-Audited			HALF YEAR ENDED Un-Audited		YEAR ENDED Audited	
								31-Dec-22
		1	Revenue from Operations	172.26	196.16	162.07	556.36	549.22
2	Net Profit/(Loss) for the period( before Tax, Exceptional and/or Extraordinary Items).	13.26	16.66	10.81	44.20	35.46	48.03	
3	Net Profit/(Loss) for the period before Tax ( after Exceptional and/or Extraordinary Items).	13.26	16.66	10.81	44.20	35.46	48.03	
4	Net Profit/(Loss) for the period after Tax ( after Exceptional and/or Extraordinary Items).	10.26	11.66	8.56	32.95	26.75	33.93	
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period(after tax) and Other Comprehensive Income(Net of Tax).	8.51	21.71	6.95	35,20	35.64	39.61	
6	Equity Share Capital( Face Value of Rs. 10/- each).	251.91	251.91	354.50	251.91	354.50	354.50	
7	Earning Per Share (Face value of Rs. 10/- each) (not annulised) (in Rs.) 1) Basic	0.41	0.46	0.19	1.31	0.59	0.74	
	2) Diluted	0.41	0.46	0.19	1.31	0.59	0.74	

#### NOTES :-

केल्याने

. 2022 करून

₹. पुढील ाकडून तुमचे वर्णन ऑण्ड **।**लेल्या तुमची व्याज. ग्रकीचे ठेवावी म्हाला कराराने

ना सर्व आणि ते येणे **बँके**ला णतीही ल्यास. मत्ता व ार राखून

ग्रचात. , गहाण

गकरिता

ा बाधा

धेकारी

- The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cll.in.
- The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 28th Jan, 2023.
- Previous figures have been regrouped/ rearranged, wherever necessary,

For and on behalf of the Board

### COLINZ LABORATORIES LTD.

CIN NO: L24200MH1986PLC041128

Dr. MANI L. S.

(Director & Company Secretary) DIN NO : 00825886)



28th Jan, 2023.

# \* FREE PRESS JOURNAL

DI. 29/01/2023

THE FREE PRESS JOURNAL www.freepressjournal.in MUMBAI | SUNDAY | JANUARY 29, 2023

### **COLINZ LABORATORIES LIMITED**

A-101, Pratik Ind. Estate, Next to Fortis Hospital, Mulund-Goregaon Link Road, Mumbai – 400 078.
(CIN NO: L24200MH1986PLC041128)

## EXTRACTS OF UN-AUDITED RESULTS FOR THE QUARTER ENDED 31st December, 2022

			ADTED ELL		( Rs. In "Lacs"		
S.		QUARTER ENDED Un-Audited			HALF YEAR ENDED Un-Audited		ENDED Audited
No.							
		31-Dec-22	30-Sep-22	31-Dec-21	31-Dec-22	31-Dec-21	31-Mar-22
1	Revenue from Operations	172.26	196.16	162.07	556.36	549.22	714.50
2	Net Profit/(Loss) for the period( before Tax, Exceptional and/or Extraordinary Items).	13.26	16.66	10.81	44.20	35.46	48.03
3	Net Profit/(Loss) for the period before Tax ( after Exceptional and/or Extraordinary Items).	13.26	16.66	10.81	44,20	35.46	48.03
4	Net Profit/(Loss) for the period after Tax ( after Exceptional and/or Extraordinary Items).	10.26	11.66	8.56	32.95	26.75	33.93
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period(after tax)	т эня	olea se	10	denivie Vitan W	America America	33.33
	and Other Comprehensive Income (Net of Tax).	8.51	21.71	6.95	35.20	35.64	39.61
6	Equity Share Capital (Face Value of Rs. 10/-'each).	251.91	251.91	354.50	251.91	354.50	354.50
7	Earning Per Share ( Face value of Rs. 10/- each) (not annulised) (in Rs.)  1) Basic  2) Diluted	0.41 0.41	0.46 0.46	0.19 0.19	1.31 1.31	0.59	0.74 0.74

#### NOTES:-

- The above is an extract of the detailed format of financial results filed with the Stock Exchange under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015. The full format of the Financial Results is available on the website of BSE at www.bseindia.com and on the Company's website at www.findoc-cil.in.
- The above financial results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their meetings held on 28" Jan, 2023.

3) Previous figures have been regrouped/rearranged, wherever necessary.

For and on behalf of the Board

COLINZ LABORATORIES LTD.

CIN NO: L24200MH1986PLC041128

Dr. MANI L. S.

(Director & Company Secretary

DIN NO: 00825886)

MUMBAI. 28<sup>th</sup> Jan,2023.

